Souhaitez-vous accéder aux communiqués récents ?

Alumis Announces Pricing of Upsized Public Offering of Common Stock

LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for...

Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market...

First patient dosed and study open in leading oncology centers in US and AustraliaPhase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and early...

BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive...

COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech...

BGB Group strengthens pharma commercialization capabilities by integrating Hayden's payer and reimbursement expertise into its advisory practice.

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Teclison Inc. announced it will participate in the ASCO Gastrointestinal Cancers Symposium, showcasing progress in its GI cancer research efforts.

Dewpoint Therapeutics launches Gates Foundation-funded initiative to build and share viral condensate phenomics atlas for HPV.